Advanced nanomaterials for modulating Alzheimer's related amyloid aggregation

55Citations
Citations of this article
49Readers
Mendeley users who have this article in their library.

Abstract

Alzheimer's disease (AD) is a common neurodegenerative disease that brings about enormous economic pressure to families and society. Inhibiting abnormal aggregation of Aβ and accelerating the dissociation of aggregates is treated as an effective method to prevent and treat AD. Recently, nanomaterials have been applied in AD treatment due to their excellent physicochemical properties and drug activity. As a drug delivery platform or inhibitor, various excellent nanomaterials have exhibited potential in inhibiting Aβ fibrillation, disaggregating, and clearing mature amyloid plaques by enhancing the performance of drugs. This review comprehensively summarizes the advantages and disadvantages of nanomaterials in modulating amyloid aggregation and AD treatment. The design of various functional nanomaterials is discussed, and the strategies for improved properties toward AD treatment are analyzed. Finally, the challenges faced by nanomaterials with different dimensions in AD-related amyloid aggregate modulation are expounded, and the prospects of nanomaterials are proposed.

Cite

CITATION STYLE

APA

Shao, X., Yan, C., Wang, C., Wang, C., Cao, Y., Zhou, Y., … Ding, S. (2022, November 21). Advanced nanomaterials for modulating Alzheimer’s related amyloid aggregation. Nanoscale Advances. Royal Society of Chemistry. https://doi.org/10.1039/d2na00625a

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free